spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  CTCL  

 HSMN NewsFeed - 4 May 2023
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2023
Soligenix Provides Regulatory Update on HyBryte(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Feb 2023
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Mar 2021
Bioniz Therapeutics Appoints Dr. Alexandre Kaoukhov to Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 May 2020
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
Biopharmaceuticals
 HSMN NewsFeed - 30 Apr 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2018
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2018
Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Aug 2013
Ceptaris Receives FDA Approval for VALCHLOR(TM) (mechlorethamine) Gel for the Treatment of Stage IA and IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma in Patients Who Have Received Prior Skin-Directed Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Aug 2013
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Feb 2013
Valeant Pharmaceuticals Acquires U.S. Rights to Targretin(R) from Eisai Inc.
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 9 May 2011
Yaupon Therapeutics Names Steve Tullman Chairman and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jan 2010
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Dec 2009
Celgene to Acquire Gloucester Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 2 Sep 2009
FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Mar 2009
U.S. FDA Approves New THERAKOS(TM) CELLEX(TM) Photopheresis System
Devices Oncology FDA
 HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Jun 2008
William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jan 2008
Gloucester Pharmaceuticals Announces New Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2007
BioCryst Provides Forodesine HCl Update
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Nov 2007
Marketing Application for Vorinostat Filed in Europe for the Treatment of Advanced, Refractory Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Oct 2007
BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Aug 2007
BioCryst Appoints Elliott T. Berger, Ph.D., Senior Vice President of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jul 2007
BioCryst Announces Realignment and Strengthening of the Company's Executive Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jul 2007
Journal of Clinical Oncology Publishes Data on ZOLINZA(TM) (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jun 2007
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
ONTAK(R) (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2007
Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Apr 2007
Cyclacel Pharmaceuticals Begins Phase II Study of Oral Sapacitabine in Patients with Advanced Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Apr 2007
BioCryst Expands Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2007
BioCryst Provides Fodosine(TM) Update
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Feb 2007
EMEA Grants Orphan Drug Designation to BioCryst's Fodosine(TM) for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Dec 2006
CuraGen and TopoTarget Announce Expansion of Belinostat (PXD101) Clinical Trial in Cutaneous T-cell Lymphoma (CTCL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for Peripheral T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Gloucester Pharmaceuticals Reports Clinically Significant Responses in Interim Analysis of Pivotal Trial for Cutaneous T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Jun 2006
ZOLINZA(TM), Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), to Receive Priority Review from U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jun 2006
Gloucester Pharmaceuticals Appoints Jean C. Nichols, Ph.D., Executive Vice President and Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Feb 2006
CuraGen and TopoTarget Initiate Phase II Clinical Trial of PXD101 for T-Cell Lymphoma
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 11

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 11 additional stories matching:
CTCL
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.